Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06480760 · ClinicalTrials.gov registry record · Phase 1

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

A Phase 1 study of Peripheral Arterial Disease, sponsored by Shahid Baba.

Recruiting
Registry status
Phase 1
Development phase
144
Enrollment target
3
Study locations

NCT06480760: Recruiting Phase 1 study of Peripheral Arterial Disease, sponsored by Shahid Baba.

NCT06480760 is a Phase 1 study of Peripheral Arterial Disease that is actively recruiting participants, run by Shahid Baba. The registered enrollment target is 144 participants, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06480760, a Phase 1 study of Peripheral Arterial Disease, is actively recruiting participants, sponsored by Shahid Baba.

RECRUITING
Registry status
Phase 1
Development phase
144 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. Previous studies with heart failure patients have shown that carnosine supplementation increases walking capacity in these patients.

Primary Outcome

Distance covered on a flat and hard surface in 6 minutes. Units: Feet

Interventions

  • DRUG Carnosine

Study Locations (3)

Kentucky

  • University of Louisville School of Medicine, Department of Medicine, Division of Environmental Medicine - Louisville
  • University Surgical Associates, 401 E. Chestnut St, Suite 710 - Louisville
  • UofL Physicians - Vascular Surgery Associates, 201 Abraham Flexner Way, Suite 1004 - Louisville

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2025-05-20
Est. Completion 2028-10-01
Phase Phase 1
Shahid Baba

2 total trials

What NCT06480760 shows while recruiting

NCT06480760 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Carnosine is the first listed.

NCT06480760 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT06480760 about?

NCT06480760 is a clinical study titled "Effects of Carnosine In Patients With Peripheral Arterial Disease Patients". The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. Previous studies with heart failure pati...

What is the current status of trial NCT06480760?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2025-05-20. Estimated completion is 2028-10-01.

What conditions does trial NCT06480760 study?

This clinical trial studies the following conditions: Peripheral Arterial Disease.

What interventions are being tested in trial NCT06480760?

The interventions under investigation include: Carnosine (DRUG).

Who is sponsoring clinical trial NCT06480760?

This trial is sponsored by Shahid Baba, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06480760 being conducted?

This trial has 3 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Arterial Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06480760's enrollment target sits among peer trials

144 32nd of 79 higher than 48 of 79 other Peripheral Arterial Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06480760, the US trial registry maintained by the National Library of Medicine. NCT06480760 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.